|
1
|
Yoshida H, Shiratori Y, Moriyama M, et al:
Interferon therapy reduces the risk for hepatocellular carcinoma:
national surveillance program of cirrhotic and noncirrhotic
patients with chronic hepatitis C in Japan. Ann Intern Med.
131:174–181. 1999. View Article : Google Scholar
|
|
2
|
Bruno S, Stroffolini T, Colombo M, et al:
Sustained virological response to interferon-α is associated with
improved outcome in HCV-related cirrhosis: a retrospective study.
Hepatology. 45:579–587. 2007.
|
|
3
|
Ikeda K, Saitoh S, Arase Y, et al: Effect
of interferon therapy on hepatocellular carcinogenesis in patients
with chronic hepatitis C: A long-term observation study of 1,643
patients using statistical bias correction with proportional hazard
analysis. Hepatology. 29:1124–1130. 1999. View Article : Google Scholar
|
|
4
|
Tanaka H, Tsukuma H, Kasahara A, et al:
Effect of interferon therapy on the incidence of hepatocellular
carcinoma and mortality of patients with chronic hepatitis C: a
retrospective cohort study of 738 patients. Int J Cancer.
87:741–749. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Poynard T, McHutchison J, Manns M, et al:
Impact of pegylated interferon alfa-2b and ribavirin on liver
fibrosis in patients with chronic hepatitis C. Gastroenterology.
122:1303–1313. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahmed F and Jacobson IM: Management of
hematologic side effects: impact on compliance and efficacy. Cur
Hepat Rep. 4:56–60. 2005. View Article : Google Scholar
|
|
7
|
Shiffman ML, Ghany MG, Morgan TR, et al:
Impact of reducing peginterferon alfa-2a and ribavirin dose during
retreatment in patients with chronic hepatitis C. Gastroenterology.
132:103–112. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McHutchson JG, Manns M, Patel K, et al:
Adherence to combination therapy enhances sustained response in
genotype-1-infected patients with chronic hepatitis C.
Gastroenterology. 123:1061–1069. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kercher KW, Carbonell AM, Heniford B, et
al: Laparoscopic splenectomy reverses thrombocytopenia in patients
with hepatitis C cirrhosis and portal hypertension. J Gastrointest
Surg. 8:120–126. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai YQ, Zhou J, Chen XD, et al:
Laparoscopic splenectomy is an effective and safe intervention for
hypersplenism secondary to liver cirrhosis. Surg Endosc.
25:3791–3797. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Murata K, Shiraki K, Takase K, et al: Long
term follow-up for patients with liver cirrhosis after partial
splenic embolization. Hepatogastroenterology. 43:1212–1217.
1996.PubMed/NCBI
|
|
12
|
Hayashi H, Beppu T, Masuda T, et al:
Predictive factors for platelet increase after partial splenic
embolization in liver cirrhosis patients. J Gastroenterol Hepatol.
22:1638–1642. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
McHutchison JG, Dusheiko G, Shiffman ML,
et al: Eltrombopag for thrombocytopenia in patients with cirrhosis
associated with hepatitis C. N Engl J Med. 357:2227–2236. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hashimoto N, Akahoshi T, Tomikawa M, et
al: Value of laparoscopic splenectomy as salvage treatment for
relapsed thrombocytopenia after partial splenic arterial
embolization. Dig Surg. 27:515–520. 2010. View Article : Google Scholar
|
|
15
|
Bisharat N, Omari H, Lavi I, et al: Risk
of infection and death among post-splenectomy patients. J Infect.
43:182–186. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Murata K, Ito K, Yoneda K, et al:
Splenectomy improves liver function in patients with liver
cirrhosis. Hepatogastroenterology. 55:1407–1411. 2008.PubMed/NCBI
|
|
17
|
Morihara D, Kobayashi M, Ikeda K, et al:
Effectiveness of combination therapy of splenectomy and long-term
interferon in patients with hepatitis C virus-related cirrhosis and
thrombocytopenia. Hepatol Res. 39:439–447. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ikezawa K, Naito M, Yumida T, et al:
Splenectomy and antiviral treatment for thrombocytopenic with
chronic hepatitis C virus infection. J Viral Hepat. 17:488–492.
2010.PubMed/NCBI
|
|
19
|
Akahoshi T, Tomikawa M, Korenaga D, et al:
Laparoscopic splenectomy with peginterferon and ribavirin therapy
for patients with hepatitis C virus cirrhosis and hypersplenism.
Surg Endosc. 24:680–685. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tomikawa M, Akahoshi T, Sugimachi K, et
al: Laparoscopic splenectomy may be a superior intervention for
cirrhotic patients with hypersplenism. J Gastroenterol Hepatol.
25:397–402. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshida D, Nagao Y, Tomikawa M, et al:
Predictive factors for platelet count after laparoscopic
splenectomy in cirrhotic patients. Hepatol Int. Sep 30–2011.(Epub
ahead of print).
|
|
22
|
Pawlotsky JM: Therapy of hepatitis C: from
empiricism to eradication. Hepatology. 43(Suppl 1): S207–S220.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zeuzem S: Heterogeneous virologic response
rates to interferon based therapy in patients with chronic
hepatitis C: who responds less well? Ann Intern Med. 140:370–381.
2004.PubMed/NCBI
|
|
24
|
Piccinino F and Coppola N: Antiviral
treatment of HCV-related cirrhosis. Dig Liver Dis. 39(Suppl 1):
S96–S101. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Di Marco V, Almasio PL, Ferraro D, et al:
Peg-interferon alone or combined with ribavirin in HCV cirrhosis
with portal hypertension: a randomized controlled trial. J Hepatol.
47:484–491. 2007.
|
|
26
|
Vezali E, Aghemo A and Colombo M: A review
of the treatment of chronic hepatitis C virus infection in
cirrhosis. Clin Ther. 32:2117–2138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakamura T, Sakata R, Ueno T, et al:
Inhibition of transforming growth factor β prevents progression of
liver fibrosis and enhances hepatocyte regeneration in
dimethylnitrosamine-treated rats. Hepatology. 32:247–255. 2000.
|
|
28
|
Akahoshi T, Hashizume M, Tanoue K, et al:
Role of the spleen in liver fibrosis in rats may be mediated by
transforming growth factor β-1. J Gastroenterol Hepatol. 17:59–65.
2002.PubMed/NCBI
|
|
29
|
Okada Y, Tsuzuki Y, Hokari R, et al:
Pressure loading and ethanol exposure differently modulate rat
hepatic stellate cell activation. J Cell Physiol. 215:472–480.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Murata K, Shiraki K, Sugimoto K, et al:
Splenectomy enhances liver regeneration through tumor necrosis
factor (TNF)-α following dimethylnitrosamine-induced cirrhotic rat
model. Hepatogastroenterology. 48:1022–1027. 2001.
|
|
31
|
Murata S, Ohkohchi N, Matsuo R, et al:
Platelets promote liver regeneration in early period after
hepatectomy in mice. World J Surg. 31:808–816. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takahashi K, Murata S, Ohkohchi N, et al:
Novel therapy for liver regeneration by increasing the number of
platelets. Surg Today. Nov 21–2012.(Epub ahead of print).
|
|
33
|
Ripoll C, Groszmann RJ, Garcia-Tsao G, et
al: Hepatic venous pressure gradient predicts development of
hepatocellular carcinoma independently of severity of cirrhosis. J
Hepatol. 50:923–928. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lok AS, Everhart JE, Wright EC, et al:
Maintenance peginterferon therapy and other factors associated with
hepatocellular carcinoma in patients with advanced hepatitis C.
Gastroenterology. 140:840–849. 2011. View Article : Google Scholar : PubMed/NCBI
|
